ReNerve (ASX:RNV) received marketing approval for its NervAlign Nerve Cuff product in Thailand, according to a Tuesday filing with the Australian bourse.
The NervAlign Nerve Cuff product is designed to safeguard repaired nerves and promote regeneration during the healing process following peripheral nerve injuries, the filing said.
The company also received an initial stocking order for NervAlign Nerve Cuff from its first hospital customer in Hong Kong, per the filing.
Shares fell 4% in midday trade Wednesday, and earlier hit an all-time low.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.